-
101دورية أكاديمية
المؤلفون: Akdeniz, D., Schmidt, M.K., Seynaeve, C.M., McCool, D., Giardiello, D., Broek, A.J. van den, Hauptmann, M., Steyerberg, E.W., Hooning, M.J.
المصدر: The Breast
مصطلحات موضوعية: Contralateral breast cancer, Metachronous, Risk factors, Systematic review, Meta-analysis
الوصف: Analysis and support of clinical decision making
العلاقة: lumc-id: 64401042; https://hdl.handle.net/1887/121115Test
-
102دورية أكاديمية
المؤلفون: Hellemond, I.E.G. van, Vriens, I.J.H., Peer, P.G.M., Swinkels, A.C.P., Smorenburg, C.H., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P. van den, Boer, M. de, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG
المصدر: International Journal of Cancer
مصطلحات موضوعية: breast cancer, aromatase inhibitor, chemotherapy-induced amenorrhea, chemotherapy-induced ovarian function failure (CIOFF), ovarian function recovery (OFR)
الوصف: The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor-positive early breast cancer after 2-3 years of tamoxifen. Patients with chemotherapy-induced ovarian function failure (CIOFF) were also eligible, but could be at risk of ovarian function recovery (OFR). The current analysis compared the survival of women with CIOFF with definitely postmenopausal women and examined the influence of OFR on survival. Therefore, we selected patients from the DATA study aged 45-57 years at randomization who had received (neo)adjuvant chemotherapy. They were classified by reversibility of postmenopausal status: possibly reversible in case of CIOFF (n = 395) versus definitely postmenopausal (n = 261). The former were monitored by E2 measurements for OFR. The occurrence of OFR was incorporated as a time-dependent covariate in a Cox-regression model for calculating the hazard ratio (HR). We used the landmark method to calculate residual 5-year survival rates. When comparing CIOFF women with definitely postmenopausal women, the survival was not different. Among CIOFF women with available E2 follow-up values (n = 329), experiencing OFR (n = 39) had an unfavorable impact on distant recurrence-free survival (HR 2.27 [95% confidence interval [CI] 0.98-5.25; p = 0.05] and overall survival (HR 2.61 [95% CI 1.11-6.13; p = 0.03]). After adjusting for tumor features, the HRs became 2.11 (95% CI 0.89-5.02; p = 0.09) and 2.24 (95% CI 0.92-5.45; p = 0.07), respectively. The residual 5-year rate for distant recurrence-free survival was 76.9% for women with OFR and 92.1% for women without OFR, and for 5-year overall survival 80.8% and 94.4%, respectively. Women with CIOFF receiving anastrozole may be at increased risk of disease recurrence if experiencing OFR. ; Experimentele farmacotherapie
العلاقة: lumc-id: 84255257; https://hdl.handle.net/1887/122854Test
-
103دورية أكاديمية
المؤلفون: Rijnsburger, A.J. (Adriana), Essink-Bot, M.L.E. (Marie-Louise), Dooren, S. (Silvia) van, Borsboom, G.J.J.M. (Gerard), Seynaeve, C.M. (Caroline), Bartels, C.C.M. (Carina), Klijn, J.G.M. (Jan), Tibben, A. (Arend), Koning, H.J. (Harry) de
المصدر: British Journal of Cancer vol. 91 no. 1, pp. 69-76
مصطلحات موضوعية: Breast cancer, High risk, Quality of life, Screening
الوصف: The effectiveness of intensive surveillance in women at high risk for breast cancer due to a familial or genetic predisposition is uncertain and is currently being evaluated in a Dutch magnetic resonance imaging (MRI) screening (MRISC) study, in which annual imaging consists of mammography and MRI. Unfavourable side effects on health-related quality of life may arise from this screening process. We examined the short-term effects of screening for breast cancer in high-risk women on generic health-related quality of life and distress. A total of 519 participants in the MRISC study were asked to complete generic health-status questionnaires (SF-36, EQ-5D) as well as additional questionnaires for distress and items relating to breast cancer screening, at three different time points around screening. The study population showed significantly better generic health-related quality of life scores compared to age-/sex-adjusted reference scores from the general population. Neither generic health-related quality of life scores nor distress scores among the study sample (n = 334) showed significant changes over time. The impact of the screening process on generic health status did not differ between risk categories. Relatively more women reported mammography as quite to very painful (30.1%) compared to MRI. Anxiety was experienced by 37% of the women undergoing MRI. We conclude that screening for breast cancer in high-risk women does not have an unfavourable impact on short-term generic health-related quality of life and general distress. In this study, high-risk women who opted for regular breast cancer screening had a better health status than women from the general population.
العلاقة: http://repub.eur.nl/pub/69797Test; urn:hdl:1765/69797
-
104دورية أكاديمية
المؤلفون: Hul, R.L. (René) van der, Seynaeve, C.M. (Caroline), Geel, B.N. (Bert) van, Verweij, J. (Jaap)
المصدر: Sarcoma vol. 7 no. 3-4, pp. 153-157
مصطلحات موضوعية: Desmoids, Methotrexate, Sarcomas, Vinblastine
العلاقة: http://repub.eur.nl/pub/69832Test; urn:hdl:1765/69832
-
105
المؤلفون: Hellemond, I.E.G. van, Smorenburg, C.H., Peer, P.G.M., Swinkels, A.C.P., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P.J. van den, Boer, M. de, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG
المساهمون: Medical Oncology, Otorhinolaryngology and Head and Neck Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, Promovendi ODB, MUMC+: MA Medische Oncologie (9)
المصدر: International Journal of Cancer, 145(5), 1325-1333. Wiley-Liss Inc.
International Journal of Cancer
International Journal of Cancer, 145(5), 1325-1333. Wiley
International Journal of Cancer, 145(5), 1325-1333. WILEY
International Journal of Cancer, 145, 1325-1333
International Journal of Cancer, 145, 5, pp. 1325-1333مصطلحات موضوعية: Cancer Research, medicine.medical_treatment, Osteoporosis, TERM DENOSUMAB TREATMENT, THERAPY, aromatase inhibitors, DOUBLE-BLIND, Fractures, Bone, 0302 clinical medicine, Bone Density, Medicine, Prospective Studies, Cancer Therapy and Prevention, Osteoporosis, Postmenopausal, tamoxifen, ADJUVANT LETROZOLE, Middle Aged, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, POSTMENOPAUSAL WOMEN, PREMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, ZOLEDRONIC ACID, Female, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, anastrozole, Anastrozole, Breast Neoplasms, 03 medical and health sciences, Breast cancer, breast cancer, adjuvant, SDG 3 - Good Health and Well-being, Internal medicine, Humans, bone health, Aromatase inhibitor, business.industry, endocrine therapy, Bisphosphonate, medicine.disease, osteoporosis, Osteopenia, Zoledronic acid, osteopenia, AROMATASE INHIBITOR, MINERAL DENSITY, business, bone mineral density, Tamoxifen
الوصف: The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast cancer previously treated with 2–3 years of tamoxifen. This planned side‐study assessed patterns of care regarding detection and treatment of osteopenia/osteoporosis, and trends in bone mineral density (BMD) during and after therapy. We registered all BMD measurements and bisphosphonate‐use. Time to osteopenia/osteoporosis was analysed by Kaplan Meier methodology. For the trend in T‐scores we used linear mixed models with random patients effects. Of 1860 eligible DATA patients, 910 (48.9%) had a baseline BMD measurement. Among patients with a normal baseline BMD (n = 417), osteopenia was observed in 53.5% and 55.4% in the 6‐ and 3‐year group respectively (p = 0.18), during follow‐up. Only two patients (3‐year group) developed osteoporosis. Of the patients with osteopenia at baseline (n = 408), 24.4% and 20.4% developed osteoporosis respectively (p = 0.89). Three years after randomisation 18.3% and 18.2% used bisphosphonates in the 6‐ and 3‐year groups respectively and 6 years after randomisation this was 23.7% and 20.9% respectively (p = 0.90) of which the majority used oral bisphosphonates. The yearly mean BMD‐change during anastrozole in the lumbar spine showed a T‐score decline of 0.075. After bisphosphonate addition the decline became less prominent (0.047 (p
What's new? Loss of bone mineral density (BMD) is a side effect of aromatase inhibitor treatment, a class of drugs that stops estrogen production in postmenopausal women with breast cancer. Here the authors examined BMD loss during and after extended adjuvant endocrine therapy, following a 2‐3 year treatment with tamoxifen, subsequent aromatase inhibitor treatment was associated with BMD decrease, but the decline was modest and partially reversible after treatment cessation. The authors concluded that extended endocrine therapy was not associated with a higher incidence of osteoporosis.وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0d75c26646b7999037a83fd370e350Test
https://doi.org/10.1002/ijc.32205Test -
106
المؤلفون: Steenbruggen, T.G., Steggink, L.C., Seynaeve, C.M., Hoeven, J.J.M. van der, Hooning, M.J., Jager, A., Konings, I.R., Kroep, J.R., Smit, W.M., Tjan-Heijnen, V.C.G., Wall, E. van der, Bins, A.D., Linn, S.C., Schaapveld, M., Leeuwen, F.E. van, Schroder, C.P., Tinteren, H. van, Vries, E.G.E. de, Sonke, G.S., Gietema, J.A.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6efb71d4171e8f9ba79ddd4ece684b5bTest
https://hdl.handle.net/1887/122857Test -
107دورية أكاديمية
المؤلفون: Meijers-Heijboer, E.J. (Hanne), Niermeijer, M.F. (Martinus), Klijn, J.G.M. (Jan), Brekelmans, C.T. (Cecile), Geel, B.N. (Bert) van, Putten, W.L.J. (Wim) van, Henzen-Logmans, S.C. (Sonja), Seynaeve, C.M. (Caroline), Menke-Pluymers, M.B.E. (Marian), Verhoog, L.C. (Leon), Ouweland, A.M.W. (Ans) van den, Bartels, C.C.M. (Carina)
المصدر: New England Journal of Medicine
مصطلحات موضوعية: Genes, BRCA1, Mastectomy, Simple, Adult, BRCA2 Protein, Breast Neoplasms/epidemiology/genetics/*prevention & control/surgery, Female, Humans, Middle aged, Mutation, Neoplasm Proteins/*genetics, Proportional Hazards Models, Prospective Studies, Research Support, Non-U.S. Gov't, Transcription Factors/*genetics
الوصف: BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the w
وصف الملف: application/pdf
العلاقة: http://repub.eur.nl/pub/9688Test; urn:hdl:1765/9688
الإتاحة: http://repub.eur.nl/pub/9688Test
-
108دورية أكاديمية
المؤلفون: Klijn, J.G.M. (Jan), Piccart, M., Burghouts, J., Duchateau, L., Becquart, D., Mignolet, F., Seynaeve, C.M. (Caroline), Beex, L.V. (Louk), Mauriac, L., Zijl, J.A. van, Veyret, C., Wildiers, J., Jassem, J.
المصدر: National Cancer Institute. Journal (Print)
مصطلحات موضوعية: Premenopause, Adult, Antineoplastic Agents, Hormonal/*therapeutic use, Breast Neoplasms/blood/*drug therapy, Buserelin/*therapeutic use, Disease-Free Survival, Drug Therapy, Combination, Estradiol/blood, Estrogen Receptor Modulators/*therapeutic use, Female, Gonadorelin/blood, Humans, Menstrual Cycle/drug effects, Middle aged, Prognosis, Prospective Studies, Risk Factors, Selective Estrogen Receptor Modulators/*therapeutic use, Survival Analysis, Tamoxifen/*therapeutic use, Time Factors, Treatment Outcome
الوصف: BACKGROUND: Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast cancer. However, tamoxifen therapy induces high levels of plasma estradiol, with unknown long-term effects. In this study, we investigated the effect of combining estrogen suppression with the luteinizing hormone-releasing hormone agonist buserelin and estradiol receptor blockade with tamoxifen to determine whether the high estradiol levels induced by tamoxifen could be reduced and whether the antitumor effects would be better. METHODS: In a three-arm, randomized, prospective trial, from 1988 through 1995, a total of 161 premenopausal patients with advanced breast cancer were randomly assigned to treatment with buserelin, tamoxifen, or both. Patients with steroid receptor-negative tumors or with tumors of unknown receptor status who had a disease-free interval of less than 2 years were excluded. The median follow-up was 7.3 years, during which 76% of the patients died, all of breast cancer. Patient and tumor characteristics were well balanced among treatment groups. All P values are from two-sided tests. RESULTS: Combined treatment with buserelin and tamoxifen was superior to treatment with buserelin or tamoxifen alone by objective response rate (48%, 34%, and 28% of patients who could be evaluated, respectively; P =.11 [chi(2) test]), median progression-free survival (9.7 months, 6.3 months, and 5.6 months; P =.03), and overall survival (3.7 years, 2.5 years, and 2.9 years; P =.01). Actuarial 5-year survival percentages were 34.2% (95% confidence interval [CI] = 20.4%-48.0%), 14.9% (95% CI = 3.9%-25.9%), and 18.4% (95% CI = 7.0%-29.8%), respectively. No differences in antitumor effects were obse
وصف الملف: application/pdf
العلاقة: http://repub.eur.nl/pub/9380Test; urn:hdl:1765/9380
الإتاحة: http://repub.eur.nl/pub/9380Test
-
109دورية أكاديمية
المؤلفون: Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-de Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Grp
المصدر: Breast Cancer Research and Treatment
الوصف: Surgical oncology
وصف الملف: application/pdf
العلاقة: lumc-id: 44393700; https://hdl.handle.net/1887/75206Test
-
110دورية أكاديمية
المؤلفون: Hellemond, I. van, Smorenburg, C.H., Peer, P., Swinkels, A., Seynaeve, C.M., Sangen, M. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F., Berkmortel, F. van den, Boer, M. de, Roos, W. de, Linn, S.C., Imholz, A., Tjan-Heijnen, V.C.
المصدر: Journal of Clinical Oncology
الوصف: Experimentele farmacotherapie
العلاقة: lumc-id: 84254729; https://hdl.handle.net/1887/122852Test
